ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Takeda, Abbott and AbbVie side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Takeda×Abbott×AbbVie×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

TakedaAbbottAbbVie
studies on the registry1,7541,3452,251
open to participants now8652133
phase 3 studies under way44074
reach primary completion within a year472490
programswith a study of their own in two years25none read70+8 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseTakedaAbbottAbbVie
Phase 1

Takeda: 1 of its 25 programs at phase 1

  1. TAK-781phase 1
4%
–

AbbVie: 28 of its 70 programs at phase 1

  1. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1
  2. surzetoclaxphase 1
  3. BTK Degrader ABBV-101phase 1
  4. ABBV-1162phase 1
  5. ABBV-1451phase 1

and 23 more — sign in to see them all

40%
Phase 2

Takeda: 5 of its 25 programs at phase 2

  1. rusfertidephase 2
  2. Anti-CCR8 Antibody-drug Conjugate TAK-188phase 2
  3. Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505phase 2
  4. TAK-411phase 2
  5. TAK-951phase 2
20%
–

AbbVie: 20 of its 70 programs at phase 2

  1. ABBV-295phase 2
  2. zumilokibartphase 2
  3. ABBV-932phase 2
  4. trosunilimabphase 2
  5. ABBV-701phase 2

and 15 more — sign in to see them all

29%
Phase 3

Takeda: 11 of its 25 programs at phase 3

  1. zasocitinibphase 3
  2. elriterceptphase 3
  3. mezagitamabphase 3
  4. TAK-360phase 3
  5. TAK-003phase 3

and 6 more — sign in to see them all

44%
–

AbbVie: 16 of its 70 programs at phase 3

  1. telisotuzumab adizutecanphase 3
  2. etentamigphase 3
  3. lutikizumabphase 3
  4. mirvetuximab soravtansinephase 3
  5. turmetabart adizutecanphase 3

and 11 more — sign in to see them all

23%
Approved, new studies

Takeda: 8 of its 25 programs at approved, new studies

  1. Immunoglobulins, Intravenousapproved, new study
  2. Brentuximab Vedotinapproved, new study
  3. Vinblastineapproved, new study
  4. Vortioxetineapproved, new study
  5. antihemophilic factor, human recombinantapproved, new study

and 3 more — sign in to see them all

32%
–

AbbVie: 6 of its 70 programs at approved, new studies

  1. upadacitinibapproved, new study
  2. risankizumabapproved, new study
  3. venetoclaxapproved, new study
  4. botulinum toxin type Aapproved, new study
  5. atogepantapproved, new study

and 1 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Takeda7 readouts · 4 phase 3

Takeda, Nov ’26: 1 program whose next study reaches primary completion

  1. TAK-360phase 3 · Nov 30 · NCT06952699

Takeda, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oveporextonphase 3 · Dec 17 · NCT07363720
·

Takeda, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zasocitinibphase 3 · Feb 5 · NCT07244263
  2. teduglutidephase 3 · Feb 10 · NCT06973304

Takeda, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. apadamtase alfaphase 3 · Mar 16 · NCT04683003

Takeda, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. TAK-003phase 3 · Apr 14 · NCT06579755
·····

Takeda, Oct ’27: 1 program whose next study reaches primary completion

  1. rusfertidephase 2 · Oct 28 · NCT07648030
Abbott0 readouts · 0 phase 3············
AbbVie34 readouts · 5 phase 3

AbbVie, Nov ’26: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-701phase 2 · Nov 0 · NCT06895343
  2. ABBV-932phase 2 · Nov 0 · NCT06846320
  3. mirvetuximab soravtansinephase 3 · Nov 0 · NCT05456685
  4. upadacitinibapproved, new study · Nov 0 · NCT06389136
  5. venetoclaxapproved, new study · Nov 0 · NCT04895436

and 1 more — sign in to see them all

AbbVie, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-295phase 2 · Dec 0 · NCT07514260
  2. emraclidinephase 2 · Dec 0 · NCT07219030
  3. lutikizumabphase 3 · Dec 0 · NCT06468228
  4. telisotuzumab adizutecanphase 3 · Dec 0 · NCT06107413

AbbVie, Jan ’27: 1 program whose next study reaches primary completion

  1. risankizumabapproved, new study · Jan 0 · NCT07466550

AbbVie, Feb ’27: 9 programs whose next study reaches primary completion

  1. [11C]ABBV-112iearly phase 1 · Feb 0 · NCT07933497
  2. ABBV-859phase 1 · Feb 0 · NCT07736638
  3. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1 · Feb 0 · NCT05512390
  4. etentamigphase 3 · Feb 0 · NCT06223516
  5. MEDI0618phase 2 · Feb 0 · NCT06602479

and 4 more — sign in to see them all

·

AbbVie, Apr ’27: 1 program whose next study reaches primary completion

  1. ABBV-1451phase 1 · Apr 0 · NCT07570147

AbbVie, May ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-1162phase 1 · May 0 · NCT07832708
  2. ABBV-243phase 1 · May 0 · NCT07306754
  3. ABBV-7828phase 1 · May 0 · NCT07856706
  4. Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969phase 1 · May 0 · NCT06318273
  5. trosunilimabphase 2 · May 0 · NCT07925983

and 1 more — sign in to see them all

AbbVie, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Jun 0 · NCT07794891

AbbVie, Jul ’27: 4 programs whose next study reaches primary completion

  1. ABBV-1606phase 1 · Jul 0 · NCT07935564
  2. azirkitugphase 1 · Jul 0 · NCT05005403
  3. surzetoclaxphase 2 · Jul 0 · NCT06291220
  4. surzetoclaxphase 1 · Jul 0 · NCT06291220

AbbVie, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. vedolizumabphase 3 · Aug 0 · NCT06880744

AbbVie, Sep ’27: 1 program whose next study reaches primary completion

  1. icalcaprantphase 2 · Sep 0 · NCT07276997
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Takeda

New programs 1

  • TAK-664approved, new study · first study · Aug 26 · Primary Immunodeficiency Diseases

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Abbott

No programs read for this company.

AbbVie

New programs 5

  • [11C]ABBV-112iearly phase 1 · first study · Nov 6
  • ABBV-7828phase 1 · first study · Sep 28
  • ABBV-1162phase 1 · first study · Sep 16
  • ABBV-253phase 1 · first study · Sep 1 · Carcinoma, Non-Small-Cell Lung
  • NOA LIFTphase 3 · first study · Aug 27

Reached a new phase 1

  • ABBV-722phase 3 · Oct 23 · Scleroderma, Systemic

Study stopped 0

None

Primary completion later 10

Where they overlap

Conditions where at least two of them have programs: 16 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionTakedaAbbottAbbVie
Crohn Disease2 of 3 · compare here

Takeda in Crohn Disease: 3 programs

  1. zasocitinibphase 3
  2. teduglutidephase 3
  3. ontamalimabphase 3

Their studies: Takeda’s studies of Crohn Disease in search

–

AbbVie in Crohn Disease: 7 programs

  1. lutikizumabphase 3
  2. vedolizumabphase 3
  3. trosunilimabphase 2
  4. ABBV-701phase 2
  5. ABBV-8736phase 2

and 2 more — sign in to see them all

Their studies: AbbVie’s studies of Crohn Disease in search

Multiple Myeloma2 of 3 · compare here

Takeda in Multiple Myeloma: 1 program

  1. mezagitamabphase 3

Their studies: Takeda’s studies of Multiple Myeloma in search

–
Arthritis, Psoriatic2 of 3 · compare here

Takeda in Arthritis, Psoriatic: 1 program

  1. zasocitinibphase 3

Their studies: Takeda’s studies of Arthritis, Psoriatic in search

–

AbbVie in Arthritis, Psoriatic: 4 programs

  1. lutikizumabphase 3
  2. ABBV-701phase 2
  3. ABBV-547phase 2
  4. risankizumabapproved, new study

Their studies: AbbVie’s studies of Arthritis, Psoriatic in search

Colitis, Ulcerative2 of 3 · compare here

Takeda in Colitis, Ulcerative: 1 program

  1. ontamalimabphase 3

Their studies: Takeda’s studies of Colitis, Ulcerative in search

–

AbbVie in Colitis, Ulcerative: 4 programs

  1. vedolizumabphase 3
  2. ravagalimabphase 2
  3. upadacitinibapproved, new study
  4. risankizumabapproved, new study

Their studies: AbbVie’s studies of Colitis, Ulcerative in search

Alzheimer Disease2 of 3 · compare here

Takeda in Alzheimer Disease: 1 program

  1. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Alzheimer Disease in search

–

AbbVie in Alzheimer Disease: 3 programs

  1. emraclidinephase 2
  2. ABBV-1758phase 2
  3. ALIA-1758phase 1

Their studies: AbbVie’s studies of Alzheimer Disease in search

Psoriasis2 of 3 · compare here

Takeda in Psoriasis: 1 program

  1. zasocitinibphase 3

Their studies: Takeda’s studies of Psoriasis in search

–

AbbVie in Psoriasis: 3 programs

  1. ABBV-295phase 2
  2. ABBV-547phase 2
  3. risankizumabapproved, new study

Their studies: AbbVie’s studies of Psoriasis in search

Depressive Disorder, Major2 of 3 · compare here

Takeda in Depressive Disorder, Major: 1 program

  1. Vortioxetineapproved, new study

Their studies: Takeda’s studies of Depressive Disorder, Major in search

–

AbbVie in Depressive Disorder, Major: 2 programs

  1. icalcaprantphase 2
  2. bretisilocinphase 2

Their studies: AbbVie’s studies of Depressive Disorder, Major in search

Renal Insufficiency2 of 3 · compare here

Takeda in Renal Insufficiency: 1 program

  1. teduglutidephase 3

Their studies: Takeda’s studies of Renal Insufficiency in search

–

AbbVie in Renal Insufficiency: 2 programs

  1. tavapadonphase 3
  2. emraclidinephase 2

Their studies: AbbVie’s studies of Renal Insufficiency in search

Cholangitis, Sclerosing2 of 3 · compare here

Takeda in Cholangitis, Sclerosing: 1 program

  1. TAK-781phase 1

Their studies: Takeda’s studies of Cholangitis, Sclerosing in search

–

AbbVie in Cholangitis, Sclerosing: 1 program

  1. vedolizumabphase 3

Their studies: AbbVie’s studies of Cholangitis, Sclerosing in search

Generalized Anxiety Disorder2 of 3 · compare here

Takeda in Generalized Anxiety Disorder: 1 program

  1. Vortioxetineapproved, new study

Their studies: Takeda’s studies of Generalized Anxiety Disorder in search

–

AbbVie in Generalized Anxiety Disorder: 1 program

  1. ABBV-932phase 2

Their studies: AbbVie’s studies of Generalized Anxiety Disorder in search

Hidradenitis Suppurativa2 of 3 · compare here

Takeda in Hidradenitis Suppurativa: 1 program

  1. zasocitinibphase 3

Their studies: Takeda’s studies of Hidradenitis Suppurativa in search

–

AbbVie in Hidradenitis Suppurativa: 1 program

  1. lutikizumabphase 3

Their studies: AbbVie’s studies of Hidradenitis Suppurativa in search

Kidney Diseases2 of 3 · compare here

Takeda in Kidney Diseases: 1 program

  1. mezagitamabphase 3

Their studies: Takeda’s studies of Kidney Diseases in search

–

AbbVie in Kidney Diseases: 1 program

  1. trifluridine tipiracil drug combinationphase 3

Their studies: AbbVie’s studies of Kidney Diseases in search

Show all 16

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Takeda 12 of 25 · Abbott 0 of 0 · AbbVie 54 of 70 programs (25 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AbbVie: 8).